1例接受奥玛单抗治疗的重症哮喘患者因COVID-19死亡的病例报告

IF 0.3 Q4 ALLERGY

Astim Allerji Immunoloji Pub Date : 2020-11-06 DOI:10.21911/aai.584

M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu

{"title":"1例接受奥玛单抗治疗的重症哮喘患者因COVID-19死亡的病例报告","authors":"M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu","doi":"10.21911/aai.584","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2020-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report\",\"authors\":\"M. Çakmak, S. B. Kaya, Ö. Bostan, G. Tuncay, E. Damadoğlu, G. Karakaya, A. Kalyoncu\",\"doi\":\"10.21911/aai.584\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma\",\"PeriodicalId\":42004,\"journal\":{\"name\":\"Astim Allerji Immunoloji\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2020-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Astim Allerji Immunoloji\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21911/aai.584\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/aai.584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 4

摘要

2019冠状病毒病（新冠肺炎）起源于中国武汉，并在世界范围内引起大流行，严重急性呼吸系统综合征冠状病毒2型感染具有极大的健康风险，特别是在慢性病患者中。人们担心新冠肺炎在严重哮喘患者中会更严重。在严重哮喘感染期间使用生物制剂治疗严重哮喘的疗效和安全性目前尚不清楚。在本病例报告中，我们介绍了一名使用奥马珠单抗五年的患者，该患者被诊断为严重哮喘，并死于新冠肺炎。据我们所知，这是土耳其第一例因新冠肺炎而死于奥马珠单抗治疗严重哮喘的患者

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases There are concerns that COVID-19 will be more severe in patients with severe asthma The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19 To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Astim Allerji Immunoloji ALLERGY-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.